LAWRENCE, Mass., July 20 /PRNewswire/ -- NxStage Medical, Inc., a medical device company that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease and acute kidney failure, announced today that it has filed a registration statement with the Securities and Exchange Commission for the proposed initial public offering of its common stock.
The lead underwriter for the offering is Merrill Lynch & Co.; Thomas Weisel Partners LLC, William Blair & Company and JMP Securities are acting as co-managers. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this offering may be obtained from Merrill Lynch, at 4 World Financial Center, New York, NY, 10080, 212-449-1000.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
NxStage Medical, Inc.CONTACT: Merrill Lynch, +1-212-449-1000
